Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMV-VST for Recalcitrant CMV in Primary Immunodeficiency
NCT07015801Active, not recruiting
- Sponsor
- University of Calgary
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of CMV-specific donor-derived T lymphocytes (University of Calgary) in cytomegalovirus infection (CMV), sponsored by University of Calgary. Primary endpoints: Feasibility of study, Incidence of Treatment-Emergent Adverse Events and 1 more. Started Apr 2025; status: active, not recruiting.
02
Drugs
CMV-specific donor-derived T lymphocytes (University of Calgary)
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT07015801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07015801.